**Study of WAL0921 in Patients With Glomerular Kidney Diseases** This study focuses on people with certain kidney diseases, like diabetic nephropathy and others less common, called glomerular kidney diseases. *Kidneys* help filter waste from the blood. *Glomerular diseases* affect these filters, causing problems like protein in urine (proteinuria). **WAL0921** is a new drug being studied to see if it helps with these conditions. This study is organized so that neither the doctors nor the participants know if they're getting WAL0921 or a placebo (a substance with no active drug) to see if the drug works. Participants will get the drug or placebo through an IV (a tube into a vein) every 2 weeks for 7 times. Afterward, they’ll be monitored for 24 weeks. **Key Points**: - The study lasts for about 9 months, including treatment and follow-up. - Participants must be adults aged 18-75 with certain kidney diseases. - People who are pregnant, had organ transplants, or have a history of substance abuse cannot join. This study aims to ensure that WAL0921 is safe and effective for kidney health.